Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018
CpG 1018
adjuvant
formulation
immunogenicity
nanoalum
nanoparticle
stability
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
26 May 2023
26 May 2023
Historique:
received:
29
03
2023
revised:
16
05
2023
accepted:
18
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Aluminum-salt vaccine adjuvants (alum) are commercially available as micron-sized particles with varying chemical composition and crystallinity. There are reports of enhanced adjuvanticity when the alum's particle size is reduced to the nanometer range. Previously, we demonstrated that a recombinant receptor-binding domain (RBD)-based COVID-19 vaccine candidate (RBD-J; RBD-L452K-F490W) formulated with aluminum hydroxide (Alhydrogel
Identifiants
pubmed: 37376419
pii: vaccines11061030
doi: 10.3390/vaccines11061030
pmc: PMC10303432
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-002740
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-027417
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260508
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-002740 and INV-027417
Pays : United States
Déclaration de conflit d'intérêts
S.A.R.-A. and J.C.L. have filed a patent related to the RBD-L452K-F490W (RBD-J) sequence. J.C.L. has interests in Sunflower Therapeutics PBC, Honeycomb Biotechnologies, OneCyte Biotechnologies, QuantumCyte, and Repligen. J.C.L’s interests are reviewed and managed under MIT’s policies for potential conflicts of interest.
Références
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34493582
NPJ Vaccines. 2018 Oct 10;3:51
pubmed: 30323958
Adv Sci (Weinh). 2017 Nov 09;5(1):1700426
pubmed: 29375970
Vaccine. 2016 Jun 8;34(27):3059-3067
pubmed: 27155490
Hum Vaccin Immunother. 2022 Nov 30;18(5):2079346
pubmed: 35666264
Semin Immunol. 2020 Aug;50:101426
pubmed: 33257234
Front Immunol. 2013 Jan 10;3:406
pubmed: 23335921
Vaccine. 2022 Nov 22;40(49):7130-7140
pubmed: 36328879
Semin Immunol. 2021 Aug;56:101544
pubmed: 34895823
EBioMedicine. 2022 Sep;83:104217
pubmed: 35970020
J Control Release. 2020 Oct 10;326:120-130
pubmed: 32585230
Micron. 2012 Feb;43(2-3):192-200
pubmed: 21831642
J Pharm Sci. 2020 Jan;109(1):476-487
pubmed: 31589875
Hum Vaccin Immunother. 2022 Nov 30;18(5):2060667
pubmed: 35471916
Sci Transl Med. 2022 Jan 26;14(629):eabj5305
pubmed: 34783582
Vaccines (Basel). 2014 Apr 14;2(2):297-322
pubmed: 26344621
Vaccine. 2000 Mar 6;18(17):1755-62
pubmed: 10699323
J Drug Target. 2018 Jun - Jul;26(5-6):474-480
pubmed: 29334279
Nanoscale. 2020 Jan 28;12(4):2515-2523
pubmed: 31930264
Vaccine. 2020 Nov 3;38(47):7533-7541
pubmed: 33039209
ACS Nano. 2013 Dec 23;7(12):10834-49
pubmed: 24261790
Vaccine. 2018 Aug 9;36(33):5020-5029
pubmed: 30037417
Vaccine. 2005 Feb 18;23(13):1588-95
pubmed: 15694511
Immunol Rev. 2022 Sep;310(1):6-26
pubmed: 35661178
Expert Rev Vaccines. 2007 Oct;6(5):685-98
pubmed: 17931150
NPJ Vaccines. 2019 Jan 3;4:1
pubmed: 30622742
Colloids Surf B Biointerfaces. 2019 Sep 1;181:648-656
pubmed: 31212137
Vaccines (Basel). 2023 Jan 11;11(1):
pubmed: 36680000
J Med Microbiol. 2012 Jul;61(Pt 7):927-934
pubmed: 22174375
Int J Mol Sci. 2022 Apr 24;23(9):
pubmed: 35563097
Methods Mol Biol. 2017;1494:15-27
pubmed: 27718183
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Ultrason Sonochem. 2011 Jan;18(1):382-8
pubmed: 20667760
J Control Release. 2014 Jan 10;173:148-57
pubmed: 24188959
Drug Deliv Transl Res. 2021 Apr;11(2):353-372
pubmed: 33598818